Biogen has announced the discontinuation of Aduhelm, its first Alzheimer’s treatment, to reallocate resources towards Leqembi, a newer drug that has shown promise in slowing the progression of the disease. This decision marks a significant shift in Biogen’s strategy, reflecting the complex challenges and the evolving landscape of Alzheimer’s treatment. Leqembi, developed in collaboration with Eisai, represents a new chapter in Biogen’s commitment to addressing Alzheimer’s, with the company aiming to enhance its launch and further innovation in its pipeline. This move underlines the pharmaceutical industry’s dedication to refining treatment options and providing hope to millions of patients and their families affected by Alzheimer’s.
Explore the full story on Alzheimer’s News Today and Medriva.
